News & Updates

DOACs for ICH survivors with atrial fibrillation? Stroke protection comes at a cost

14 Feb 2025 by

For survivors of intracerebral haemorrhage (ICH) with atrial fibrillation (AF), the use of direct oral anticoagulants (DOACs) works to prevent ischaemic stroke events, but this benefit appears to be offset by major bleeding side effects, as shown in the open-label, phase III PRESTIGE-AF trial.

DOACs for ICH survivors with atrial fibrillation? Stroke protection comes at a cost

14 Feb 2025

Studies support nifedipine for postpartum hypertension management

14 Feb 2025 by

Data presented at SMFM 2025 favour nifedipine over labetalol for the management of hypertension in the postpartum period.

Studies support nifedipine for postpartum hypertension management

14 Feb 2025

Rezivertinib bests gefitinib in first-line treatment of advanced EGFR-mutant NSCLC

14 Feb 2025

In the first-line treatment of patients with EGFR-mutated locally advanced or metastatic non–small-cell lung cancer (NSCLC), the novel third-generation EGFR tyrosine kinase inhibitor rezivertinib yields superior overall efficacy and progression-free survival (PFS) when compared with gefitinib, with no new safety signals, according to the phase III REZOR trial.

Rezivertinib bests gefitinib in first-line treatment of advanced EGFR-mutant NSCLC

14 Feb 2025

Esophageal cancer responds well to neoadjuvant chemoradiotherapy plus immunotherapy

12 Feb 2025 by

When treating patients with locally advanced esophageal squamous cell carcinoma (ESCC) in the neoadjuvant setting, chemoradiotherapy with or without sintilimab results in significantly higher pathological complete response (pCR) rates compared with chemotherapy plus sintilimab, according to preliminary data from the phase III SCIENCE trial from China.

Esophageal cancer responds well to neoadjuvant chemoradiotherapy plus immunotherapy

12 Feb 2025

Peginterferon α-2b may deter growth, thyroid function in children with CHB

12 Feb 2025 by

Treatment with peginterferon (PegIFN) α-2b appears to inhibit the growth of and thyroid function in children with chronic hepatitis B (CHB), suggests a study.

Peginterferon α-2b may deter growth, thyroid function in children with CHB

12 Feb 2025

Glutamatergic meds beneficial in obsessive-compulsive disorder

12 Feb 2025

Glutamatergic medications appear to be efficacious in the treatment of individuals with obsessive-compulsive disorder, according to the results of a meta-analysis.

Glutamatergic meds beneficial in obsessive-compulsive disorder

12 Feb 2025

Propranolol lowers risk of ischaemic stroke in women with migraine

12 Feb 2025 by

Treatment with propranolol, a non-selective beta-blocker medication widely used to prevent migraines was associated with a significant reduction in the risk of ischaemic stroke in women with migraine, according to a preliminary study presented at ISC 2025.

Propranolol lowers risk of ischaemic stroke in women with migraine

12 Feb 2025

Stroke patients with NSAID allergy labels have poorer treatment outcomes

12 Feb 2025 by

Stroke patients with NSAID allergy labels have significantly higher mortality, peripheral vascular disease (PVD) and major adverse cardiovascular events (MACE) than those not labelled with NSAID allergies, and the rate of mislabelled NSAID allergy is high, a study by the University of Hong Kong (HKU) has found.

Stroke patients with NSAID allergy labels have poorer treatment outcomes

12 Feb 2025

Psilocybin shows promise for treatment-resistant depression

11 Feb 2025 by

The use of single-dose psilocybin offers potential safety and efficacy in patients with severe treatment-resistant depression (TRD), a study has shown.

Psilocybin shows promise for treatment-resistant depression

11 Feb 2025

Abelacimab outperforms rivaroxaban for AF patients at risk of stroke

11 Feb 2025

In the treatment of patients with atrial fibrillation (AF) and moderate-to-high risk of stroke, abelacimab appears more beneficial than rivaroxaban, having been associated with lower free factor XI levels and fewer bleeding events in the phase IIB AZALEA–TIMI 71 study.

Abelacimab outperforms rivaroxaban for AF patients at risk of stroke

11 Feb 2025

News & Updates

Filter by Specialty:

Specialty:

DOACs for ICH survivors with atrial fibrillation? Stroke protection comes at a cost

DOACs for ICH survivors with atrial fibrillation? Stroke protection comes at a cost

Studies support nifedipine for postpartum hypertension management

Studies support nifedipine for postpartum hypertension management

Rezivertinib bests gefitinib in first-line treatment of advanced EGFR-mutant NSCLC

Rezivertinib bests gefitinib in first-line treatment of advanced EGFR-mutant NSCLC

Esophageal cancer responds well to neoadjuvant chemoradiotherapy plus immunotherapy

Esophageal cancer responds well to neoadjuvant chemoradiotherapy plus immunotherapy

Peginterferon α-2b may deter growth, thyroid function in children with CHB

Peginterferon α-2b may deter growth, thyroid function in children with CHB

Glutamatergic meds beneficial in obsessive-compulsive disorder

Glutamatergic meds beneficial in obsessive-compulsive disorder

Propranolol lowers risk of ischaemic stroke in women with migraine

Propranolol lowers risk of ischaemic stroke in women with migraine

Stroke patients with NSAID allergy labels have poorer treatment outcomes

Stroke patients with NSAID allergy labels have poorer treatment outcomes

Psilocybin shows promise for treatment-resistant depression

Psilocybin shows promise for treatment-resistant depression

Abelacimab outperforms rivaroxaban for AF patients at risk of stroke

Abelacimab outperforms rivaroxaban for AF patients at risk of stroke